A recent report from CB Insights sheds fresh light on the harsh realities facing new ventures. Researchers examined 431 venture-backed startups that shut down since 2023, drawing from founder statements, shutdown announcements, and public post-mortems. After identifying clear causes for 385 of them, the data reveals that failures rarely stem from a single issue. Multiple factors often overlap, pushing companies toward collapse in today’s tighter funding environment.
According to the update from CB Insights, the most common endpoint, cited in 70 percent of cases, is simply running out of cash.
Yet this is rarely the root problem; it marks the final chapter after deeper flaws surface.
Startups in the study raised a median of $11 million, but many exhausted reserves amid shifting investor sentiment.
High-profile examples include healthcare AI firm Olive and digital freight platform Convoy—each once valued near $4 billion—both folding after burning through nearly $1 billion in funding.
The takeaway is clear: capital cannot rescue a business if foundational weaknesses remain unaddressed.
Close behind, at 43 percent, stands poor product-market fit.
Roughly two-thirds of these cases involved early-stage companies that never located viable customers.
Even later-stage firms sometimes built on fleeting early traction that failed to scale.
A notable illustration is Zume, which raised hundreds of millions before pivoting from robotic pizza to sustainable packaging, only to discover no sustainable market existed.
This mismatch drains resources and erodes investor confidence long before the bank account hits zero.
External pressures played a role in 29 percent of shutdowns, with bad timing or unfavorable macroeconomic conditions proving especially lethal in hype-heavy sectors.
Climate tech, food innovation, and blockchain startups suffered disproportionately after the 2021–2022 capital surge failed to translate into lasting demand.
Alt-protein ventures like New Age Meats and NFT platforms like RECUR illustrate how rapidly market enthusiasm can evaporate.
Another 19 percent collapsed under unsustainable unit economics—models where customer acquisition or delivery costs simply outstripped revenue. Emerging-market fintechs were hit hardest once cheap capital dried up, forcing them to confront unprofitable operations head-on.
Sector patterns add nuance.
Healthcare and biotech recorded the highest failure count (62 companies) and capital destruction ($5.1 billion), largely due to lengthy clinical trials.
Fintech followed closely, with many early-stage, non-U.S. firms struggling. Food and agriculture ranked third, driven by challenges in alternative proteins.
Warning signals often appeared well in advance.
CB Insights’ health-scoring tool showed a 15 percent average decline in the year before closure for most tracked companies.
Partnership activity dropped sharply, headcounts shrank in two-thirds of cases, and nearly a quarter lingered as “walking dead” firms for over three years post-fundraise.
Ultimately, the report underscores that startup mortality follows predictable patterns yet resists simple fixes.
Founders who validate demand early, monitor unit economics relentlessly, and prepare for macro shifts stand the best chance of beating the odds.
CB Insights concluded that in an era of relatively scarce funding, these insights serve as a timely roadmap for building resilient businesses rather than chasing fleeting trends.